HEMOPHILIA A AND B
-
CHS replies to Quebec’s INESSS following its shocking report on the funding of Hemlibra
The Institut national d’excellence en santé et en services sociaux (INESSS) released its recommendation on funding Hemlibra (emicizumab) for the treatment of severe hemophilia A...
-
Fitusiran trial restarts with new controls
BRUSSELS – During the European Association for Haemophilia and Allied Disorders (EAHAD) virtual congress session on the latest clinical trial, Dr. Shauna Anderson, representing Sanofi,...
-
Community awaits decisions on access to Hemlibra
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...
-
Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for...
-
FAQs – COVID-19 vaccine and bleeding disorders
The Association of Hemophilia Clinic Directors of Canada (AHCDC) has issued a message to address the most frequent questions asked with regards to the COVID-19...